page-title

Overview – Alzheimer’s & dementia diagnostics

We have developed a highly predictive, accurate, method for identification of Alzheimer’s Disease, and its discrimination from other forms of dementia.  We are using advances in image analysis and machine learning to overcome hurdles to reliable, early diagnosis.

The Need Alzheimer’s Disease is a devastating neurodegenerative disorder that affects the lives of more than 5.5 million people in the United States alone, in addition to their families and caregivers.  It is estimated that 1 in 8 of the 78 million baby boomers today will develop the disease.  Currently, disease confirmation occurs only with a post-mortem exam of the brain.  An estimated 50% of Alzheimer’s Disease patients are undiagnosed, and misdiagnosis occurs in at least 20% of cases.  Even today, early diagnosis of Alzheimer’s Disease can facilitate prescription of medicines that slow symptom progression. As promising drugs reach the market, early detection will become vital, since early intervention is key to impacting this disease, which begins long before symptoms emerge.

Hypometabolism in Alzheimer's DiseaseImaging as a Biomarker… Changes in brain activity and pathology occur before symptoms of Alzheimer’s Diseease are evident, and continue during disease progression.  Neuroimaging of brain activity and structure can identify these changes.  However, it is essential to extract critical information from the images and, for neuronal function assessment, to distill complex data into interpretable patterns, which current methods do not.

Our Solution… We are applying proprietary image analysis technology to differentiate between dementias, and across dementia stages.  This work and our core technologies have been sponsored in part by the Alzheimer’s Drug Discovery Foundation, the National Science Foundation, and the National Institutes of Health.